Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Jürgen WolfTakashi SetoJi-Youn HanNoemi ReguartEdward B GaronHarry J M GroenDaniel S W TanToyoaki HidaMaja de JongeSergey V OrlovEgbert F SmitPierre-Jean SouquetJohan VansteenkisteMaximilian HochmairEnriqueta FelipMakoto NishioMichael ThomasKadoaki OhashiRyo ToyozawaTobias R OverbeckFilippo de MarinisTae Min KimEckart LaackAnna RobevaSylvie Le MouhaerMaeve Waldron-LynchBanu SankaranO Alejandro BalbinXiaoming CuiMonica GiovanniniMikhail AkimovRebecca S Heistnull nullPublished in: The New England journal of medicine (2020)
Capmatinib showed substantial antitumor activity in patients with advanced NSCLC with a MET exon 14 skipping mutation, particularly in those not treated previously. The efficacy in MET-amplified advanced NSCLC was higher in tumors with a high gene copy number than in those with a low gene copy number. Low-grade peripheral edema and nausea were the main toxic effects. (Funded by Novartis Pharmaceuticals; GEOMETRY mono-1 ClinicalTrials.gov number, NCT02414139.).